Barbiturates are central nervous system depressant drugs that have been used to treat seizures, insomnia, migraines, and more. However, they are not as commonly used today due to their side effects ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB ...

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while ...

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund ...

In order to overcome this situation, the GHIT Fund has decided to invest approximately JPY 280 million (USD 2.0 million1) in a project led by US-based non-profit organization Drugs & Diagnostics for ...

The historic bell stolen from outside S. Geiger Public School in Massey in October was located by OPP in a pickup truck being ...

"We are pleased with our operational and clinical execution this quarter and look forward to sharing additional clinical data ...

Completed enrollment in the Phase 3 ORCA-OL clinical trial and announced first Data Safety Monitoring Committee Meeting ...

When you need to work with the health care provider you have, here’s how to advocate for yourself, even while wearing a ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

Platinum Asset Management's biotech specialist Dr Bianca Ogden outlines the major opportunities she is seeing in the sector.